• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 2
  3. Authors

Online ISSN: 2515-8260

Volume8, Issue2

Serum Macrophage Migration Inhibitory Factor Level In Patients With Ankylosing Spondylitis And Its Relation To Disease Activity

    Ibrahim Tharwat Abdelal Mirvat Abdel Hameed Eltoukhy Ahmed Mohammed Baraka Mohammed Abdelrahman Ibrahim

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 2, Pages 2438-2445

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Ankylosing Spondylitis (AS) is a chronic inflammatory form of arthritis that predominantly affects the axial joints and has a global prevalence of 1%. It is the most commonly occurring form of spondyloarthropathy. Macrophage migration inhibitory factor (MIF) is a potent pro-inflammatory cytokine implicated in several diseases
including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic vasculitis and ankylosing spondylitis Objective: To determine the serum levels of macrophage migration inhibitory factor in ankylosing spondylitis patients and to find out its possible correlation with disease activity. Patients and methods: This study was a case-control study conducted on 52 subjects (21 Ankylosing Spondylitis “AS”), and 21 healthy controls; to determine the serum levels of macrophage migration inhibitory factor (MIF) in ankylosing spondylitis patients and to find out its possible correlation with disease activity. Results: Our results showed statistically significant difference between the studied groups regarding MIF (significantly higher in AS group). Conclusion: MIF appears to have the unique ability to drive inflammation and could play an important role in the pathogenesis of AS.
Keywords:
    Ankylosing Spondylitis (AS) Macrophage migration inhibitory factor (MIF) spondyloarthropathy
  • PDF (398 K)
  • XML
(2021). Serum Macrophage Migration Inhibitory Factor Level In Patients With Ankylosing Spondylitis And Its Relation To Disease Activity. European Journal of Molecular & Clinical Medicine, 8(2), 2438-2445.
Ibrahim Tharwat Abdelal; Mirvat Abdel Hameed Eltoukhy; Ahmed Mohammed Baraka; Mohammed Abdelrahman Ibrahim. "Serum Macrophage Migration Inhibitory Factor Level In Patients With Ankylosing Spondylitis And Its Relation To Disease Activity". European Journal of Molecular & Clinical Medicine, 8, 2, 2021, 2438-2445.
(2021). 'Serum Macrophage Migration Inhibitory Factor Level In Patients With Ankylosing Spondylitis And Its Relation To Disease Activity', European Journal of Molecular & Clinical Medicine, 8(2), pp. 2438-2445.
Serum Macrophage Migration Inhibitory Factor Level In Patients With Ankylosing Spondylitis And Its Relation To Disease Activity. European Journal of Molecular & Clinical Medicine, 2021; 8(2): 2438-2445.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 24
  • PDF Download: 33
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  info@ejmcm.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

Editorial Team:  editor@ejmcm.com

For Special Issue Proposal : chiefeditor.ejmcm@gmail.com / info@ejmcm.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus